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ABSTRACT   
Current in vitro cancer models used for screening potential new therapeutic agents are often 2D monolayers of cells 
grown on the bottom of a petri dish or culture flask. These simplistic models lack many of the important biological 
features of in vivo tissue growth, such as the presence of an extracellular matrix (ECM) and cell interactions associated 
with this in a 3D structure. The use of spheroids for drug testing has gone some way to address the limitations of 2D 
cultures, however spheroids are still typically handled in static environments that neglect important physical aspects of 
the microenvironment present in vivo, such as fluid flow and associated shear stresse . In addition, assays involving 
spheroids still require many manual pipetting steps in which fluid is replaced in a single fluidic operation which is labor 
intensive, can be damaging to spheroid structural integrity and is an actionthat is physiologically incorrect. Here we 
present a microfluidic platform for the high-throughput trapping, culture and exposure of 3D co-culture spheroids to 
drugs under physiologically relevant fluid flow. The device is self-supportive, allowing multiple devices to be in an 
incubator at once without peripheral pumps. Spheroids can be monitored in situ with microscopy and the device is 
designed such that spheroids can be recovered for quantitative off-chip analysis. As a first demonstration, the 
effectiveness of co-delivering ultrasound (US) triggered microbubbles (MBs) with doxorubicin (DOX) was evaluated. 
Spheroids exposed to 3 µM DOX co-delivered with MBs showed a 51% reduction is spheroid viability compared to a 
25% reduction in viability of free DOX alone. 
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1. INTRODUCTION  
Inadequate in vitro models, such as 2D monolayer cultures, are being blamed for the difficulty in translating in vitro drug 
screening outcomes to in vivo models, causing a failure in the drug discovery pip line. It is thought that 2D cultures lack 
the biological complexity of in vivo tissues, many features of which are thought to relate to drug resistance, such as the 
presence of an ECM and fluid flow. 3D spheroid culture models have been developed to overcome many of these 
shortcomings, using aggregates of multiple cell types to form 3D tumour mdels in which cells grow in a more natural 
3D structure and produce ECM. In addition, the in vivo structure of solid tumours is better modelled in spheroids, 
displaying features such as a necrotic, hypoxic core followed by layers of quiescent cells surrounded by a rapidly 
proliferating outer layer 1,2. These models are more biologically accurate to in vivo tumors and have been shown to better 
predict the clinical effects of new drugs compared to 2D cultures 3–6 . One of the reasons for 3D spheroids being a more 
accurate predictor of drug outcomes in vivo is due to the presence of an ECM in co-culture models. Fibroblasts are 
responsible for laying down the proteins associated with the ECM, such as collagen th t contribute to the mechanical 
‘stiffness’ of tumors. This rigidity associated with the ECM can act as a physical barrier to drug penetration, preventing 
cells in deeper layers of the tumour being exposed to effective drug levels and resulting in treatment failure. 
When MBs are exposed to US, they oscillate and certain US conditions can cause the MB to collapse, known as MB 
destruction. When MBs are in close proximity to a cell this oscillation and collapse can create an effect called 
sonoporation in which small holes are punctured in cell membranes. This phenomenon offers a promising solution to the 
issue of drug penetration and has been studied extensively as a method by which drugs can be delivered to cells 7–12. The 
 
 
 
 
 
 
majority of these studies however, have been conducted on 2D monolayers of cells, meaning MB effectiveness in 3D 
cultures is still relatively undocumented. Recent studies have begun testing MB therapies on 3D cultures, observing the 
effects of delivering liposomal drugs conjugated to MBs. Roovers et al have shown that MB-induced sonoporation 
increases delivery of liposomal drugs to the outer spheroid layers, which then act as reservoirs slowly releasing drug. 
This was observed to increase drug effectiveness compared to LS alone however, no overall increase in drug 
effectiveness was observed compared to free drug 13. To date, MB – spheroid interactions have been performed in static 
conditions, neglecting the physical microenvironment of fluid flow.  
Here we present a microfluidic platform for high-throughput handling of spheroids for drug screening that features 
constant fluid flow at physiologically relevant velocities. The devices features an array of traps for capture and culture of 
pre-grown spheroids that can be reversed in function for the recovery f spheroids from the device. In addition, fluid 
flow is generated by integrated fluid reservoirs and hydrostatic pressure so no peripheral pumps are required, facilitating 
high numbers of device loading into an incubator. The platform was used to investigate the effect of co-delivering DOX 
with MB and US to colorectal and fibroblast co-culture spheroids under flow. We show that the presence of MBs with an 
US trigger with free DOX increases drug penetration and decreases cell viability (51%) compared to free DOX alone 
(75%). 
2. EXPERIMENTAL 
2.1 Reagents and assays 
Colorectal HCT116 tumour cells and Human Foetal Foreskin Fibroblast (HFFF2) cells were grown and maintained in 
DMEM 10% FBS (Thermo Fisher), 1% Glutamax (Gibco) in an incubator at 37oC, 5% CO2. Prior to spheroid seeding, 
cell media was removed, the cells washed with PBS (+Ca, +Mg Gibco) then detached with TrypLE Express (Gibco). 
Cell concentrations were determined using a haemocytometer after which cells were suspended in a 1:1 ratio at a 
concentration of 7.5 x 102 cells/mL. 200 µL of cell suspension was seeded into ultra-low attachment 96 well plates 
(Corning, Costar) and spheroids allowed to form for 5 days. DOX (100mg, Generon) was dissolved in 5 mL DMSO then 
further diluted in DMEM to the required concentration. DMSO concentration was kept below 0.5% to prevent any 
reduction in cell viability.  
CellTiter-Glo 3D cell viability assay (Promega) was used as an endpoint assay to determine spheroid viability. Spheroids 
were retrieved off chip 48 hours after exposure by withdrawing the chamber contents from the inlet and 100 µL of the 
assay reagent mixed with the spheroids in an opague-walled 96 well plate. After incubation at room temperature for 30 
min the luminescence was recorded on a plate reader (SpectraMax M2E, Molecular Devices) as per assay instructions. 
MBs were prepared from a mixture of DPPC and DPSE-PEG2000 in a 95:5 molar ratio nd a total lipid concentration of 
2 mg/mL-1 and produced using a microfluidic microspray device to produce 108 MBs/mL with an average diameter 
between 1 -2µm.   
2.2 Microchip fabrication 
Devices were fabricated in polydimethylsiloxane (PDMS, Sylgard 184, Dowsil) using standard photolithography and 
soft lithography techniques 14,15. Briefly, SU8-2075 photoresist was spin coated onto a 3-inch silicon wafer then baked 
for 90 minutes. This process was repeated giving a total resist height of approximately 350 µm. 375 nm UV laser 
selectively expose the photoresist and pattern the microfluidic design. PDMS was mixed in a 10:1, base: curing agent 
ratio, poured onto the wafer and desiccated for 40 minutes to remove any bubbles. PDMS was then cured at 80oC for an 
hour. Devices were then cut, hole-punched and bonded to PDMS coated glass microscope slides using oxygen plasma. 
Reservoirs were fabricated from polycarbonate (Engineering & Design Plastics). Lids were fabricated from delrin (Par-
group) then 0.22 µm PTFE filters (Cole-Parmer) glued on to prevent bacterial contamination of the media.   
2.3 Experimental set-up and methodology 
10 spheroids, with a diameter within the range 280 - 330 µm, were loaded into each inlet reservoir and allowed to flow 
into the device under hydrostatic pressure. The hydrodynamic force fr m fluid flow ensured that spheroids remained in 
their traps, unless subject to backflow. Once sufficient numbers of spheroids had been trapped, media from both 
reservoirs was removed and the therapeutic compound added to the inlet reservoir. For MB exposures, MBs were 
directly pipetted into the channel through the reservoir, preventing MBs from rising to the top of the reservoir. 
Therapeutic exposure was stopped by simply removing all compound-containing media and refilling the inlet reservoir 
 
 
 
 
 
 
with fresh media. Microfluidic devices were insonated using a 2.25 MHz centre frequency un-focused transducer (V323-
SM, Olympus, US). US pulse for MB destruction was controlled by a function generator (TG5011, Agilent 
Technologies, UK) and consisted of a duty cycle of 1 %, pulse repetition frequency of 1 kHz and total duration of 2 
seconds. Transducer output was calibrated to provide a peak negative pressure of  0.81 ± 0.04 MPa when driven by a +53 
dB RF power amplifier (A150, Electronics % Innovation, US). The transducer was coupled to the top of the microfluidic 
device via a gel pad (Aquaflex, Parker Laboratories, US). A Leica DMi8/SP8 confocal microscope system was used for 
fluorescence imaging of spheroids on-chip. Doxorubicin and NucRed Dead dye were xcited sequentially using 488 nm 
OPSL and 638 nm Diode lasers, respectively. A 10x objective was used to image spheroids in 5 µm Z-stack slices.  
 
3. RESULTS AND DISCUSSION 
3.1 Device optimization. 
For any drug screening assay, the number of samples and subsequent statistical analysis is hugely important. Therefore 
in order to trap the maximum number of spheroids, the spheroid size and microfluidic trap dimensions were optimized. 
Figure 1a shows a brightfield microscopy image of 7 spheroids trapped on a single device. The traps were designed 
similar to those be di Carlo et al. featuring a ‘pocket’ in which an object such as a cell sits under constant flow16. The 
subsequent filling up of the traps depends on the offset of downstream aps relative to those upstream and a balance of 
fluidic resistances. The device reported here was designed to trap multi-cellular spheroids rather than single cells. The 
diameter of the pocket width was approximately 330 µm, the width of the trap exhaust channel was 150 µm and the total 
depth of the device was 350 µm. The size of the spheroid is critical to the succ ss of the device, as smaller spheroids will 
not be trapped while larger spheroids will not flow through the array.  
 
 
 
Figure 1. a) Microscopy image of spheroids (~ 300 µm) trapped in a microfluidic trap array. b) Plot of average spheroid size 
(220 – 320 µm) against device trapping efficiency (10 – 70%). As spheroid size increases, spheroid trapping efficiency also 
increases.  
 
Figure 2b shows a plot of average spheroid size against trapping efficiency (dtermined by the number of available traps 
and those that are occupied after loading). The size of the spheroids tested w re between 220 and 300 µm in diameter. 
The trapping efficiency is seen to increase with increasing spheroid size, with spheroids of ~300 µm having the highest 
trapping efficiency of 70%. Spheroids larger than 350 µm were found to stick in the channels due to the height of the 
device. Therefore all future experiments were performed using spheroids of approximately 300 µm in diameter. 
3.2 Proof of principle DOX and MB co-delivery. 
In order to demonstrate both the device as a platform for rapid drug screening against 3D co-cultures and MBs as an 
effective therapeutic, pre-grown spheroids of HT116 and HFFF2s were trapped and exposed to 3 µM free DOX, free 
DOX + US trigger and 3 µM DOX + MBs with US destruction trigger as described in the experimental section. The 
 
 
 
 
 
 
concentration of 3 µM DOX was determined by producing a dose-response curve for concentrations of 0 – 10 µM with 
respect to spheroid viability (data not shown). The microfluidic device featured integrated reservoirs for fluid handling, 
in which the height difference between the inlet and the outlet provided hydrostatic pressure, which was optimized to 
drive flow at velocities similar to those observed in capillaries (0.3 – 1 mm/s). The devices therefore did not require any 
peripheral instruments such as syringe pumps and could be loaded in high umbers into a standard incubator. For the 
following study, spheroids were loaded onto 34 chips giving a spheroid number of n=162 and exposed to DOX for 8 h. 
DOX containing media was then replaced with fresh media and the spheroids allowed to grow f r a further 48 h. After 
48 h, NucRed stain was added to the device and washed off after 30 min to visualize cell death. Spheroids were imaged 
in situ using confocal fluorescence microscopy to observe DOX accumulation through its intrinsic fluorescent signal and 
corresponding cell death. 
 
 
 
Figure 2. Bright field and confocal fluorescence images of spheroids in traps shown in bright field (first column), DOX 
emission (second column) and red dead stain (third column). a) Control with ut DOX exposure b) 3 µM free DOX c) 3 µM 
free DOX with US exposure and d) 3 µM DOX co-delivered with MBs and US exposure.  
 
Figure 2 (a-d) is an image panel showing spheroids in traps imaged using bright field (first column) and fluorescence 
microscopy (column two and three). The bright field images show an decreas  in the structural integrity of spheroids 
 
 
 
 
 
 
compared to the control (a) as spheroids are exposed to 3 µM DOX (2b), 3 µM DOX with US exposure (2c) and finally, 
3 µM DOX co-delivered with MBs with US exposure (2d). The loss of structural integr ty through images a-d was due to 
the increase in the penetration of the DOX, which can be seen in the DOX channel in Figure 2 (a-d) with the inclusion of 
US and then MBs and US and the subsequent increase in cell death, as seen in by NucRed stain figure 2 (a-d) third 
column. As cells died, the cell-cell adhesion breaks down, the core density decreases and the spheroid breaks apart under 
flow. This effect directly correlates to the increase in DOX penetration and retention seen in column two, green signal. 
The presence of the US exposure increased DOX penetration into the spheroid and resulte  in a slight increase in the 
dead stain signal compared to free DOX alone. This increase in drug penetration and subsequent cell death can be 
attributed to an increase in cell permeability due to the exposure to US, an effect that has been documented in the 
literature 17,18. However the co-delivery of free DOX with MBs and US exposure shows the greatest loss of spheroid 
integrity and increase in DOX signal after 48 hours, suggesting the bursting of MBs in the vicinity of the spheroids 
increased drug penetration. This also correlated with increased NucRed staining, suggesting high cell death. MB 
destruction under US causes localized shock waves that can penetrate cell membranes, increasing the number of pores by 
which the drug could enter the cell. 
In order to quantify cell viability in these studies, spheroids were recovered from the devices and subjected to the 
CellTiter-Glo 3D cell viability assay as described in the experimental section. Figure 3 shows a b xplot of cell viability 
(as a percentage standardized to the control), for each exposure study (free DOX, DOX + US and DOX + US + MBs).  
 
Figure 3. Boxplot showing spheroid viability in % against each exposure study, free DOX (blue), free DOX with US trigger 
(red) and free DOX co-delivered with US trigger (Red). Statistical significance was calculated using a Mann-Whitney (MW) 
non-parametric t-test with values <0.0001 (****) and 95% confidence i t rval (C.I.) test performed on each data set. 
 
The cell viability for free DOX was 75 (± 4)% with a decrease with the addition of the US trigger to 61 (± 1)% and 
further decrease to 48 (± 2)% for co-delivery with MBs with US trigger. These results clearly show the impact of the 
presence of MBs and US on the penetration of DOX and subsequent cell death in CRC spheroids. The decrease in cell 
viability of 26% when co-delivering MBs with the US trigger compared to free DOX alone suggests the destruction of 
the MBs causes an increase in DOX penetration into cells, which results in an increase in cell death and thus increasing 
DOX efficacy. A similar spheroid viability was observed with the use of 5 µM DOX (45 (± 9) %), thus showing an 
increase in DOX efficacy of approximately 66% when co-delivered with MBs. These effects have been observed in 
previous MB studies 19–21. The design of the microfluidic platform allowed for large numbers of spheroids (n = 161) to 
be analyzed under the same conditions and therefore statistical tests to be performed on the data. A MW t-test was 
 
 
 
 
 
 
performed to determine their statistical significance and P-values in each case were found to be <0.0001 (****), 
confirming the reliability of the results. 95% C.I. calculations gave values of ± 3.6 %, ± 0.8 % and ± 2 % for DOX only, 
DOX + US and DOX, US + MB respectively. 
4. CONCLUSIONS 
We have demonstrated a microfluidic platform for the high-throughput exposure of 3D co-culture spheroids to 
therapeutic agents under continuous flow conditions. The device allows for the capture, culture and exposure of 
spheroids to drugs with minimal spheroid handling and is designed so that many devices can be used in parallel in an 
incubator. Devices trap spheroids with ~70% efficiency and spheroids can be recov red from the device for off-chip 
testing. Using this platform, we show how MBs mediated drug delivery increases the fficacy of DOX therapy in 3D 
CRC co-cultures under physiological flow conditions, a study that has not yet been undertaken. Free DOX co-delivered 
with MBs and triggered using US was shown to decrease spheroid viability by 51% compared to a decrease in viability 
of 25% using free DOX alone. The microfluidic device is versatile, so that spheroids of different cancer models could be 
used along with different potential therapeutics. Spheroids can be monitored in situ with microscopy or recovered for 
off-chip assessment, such as viability assays or genetic testing.  
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